Quantcast

Industry news that matters to you.  Learn more

Power3 Medical to Publish Medical Breakthrough Documented During Clinical Trials of Power3 Medical’s Flag Ship NuroPro(R) Diagnostic

Power3 Medical Products, Inc. (OTCBB: PWRM – News) announced today that, in collaboration with Lourdes R. Bosquez, MD, it has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro® protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept® (Donepezil HCl, Pfizer – NYSE: PFE), Exelon® (Rivastigmine, Novartis – NYSE: NVS), and Namenda® (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.

Van Andel Research Institute to Utilize Aushon BioSystems’ Microarray Technology

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, announced today that the Van Andel Research Institute (VARI), part of the Van Andel Institute, will utilize the Aushon 2470 Arrayer technology in its Laboratory of Cancer Immunodiagnostics to advance research efforts focusing on developing novel protein analysis methods to identify and study protein abnormalities in the blood of cancer patients. The goal of the research is to develop blood tests for the early detection or more accurate diagnosis of cancer.